{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:02:20Z","timestamp":1780549340312,"version":"3.54.1"},"reference-count":63,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Background: Osteoporosis\/osteoporotic fractures are identified in both hypercalcemic (HC-HPT) and normocalcemic variant (NC-HPT) of primary hyperparathyroidism (HPT) at various rates. Objective: Noting the need of modern society to easily assess the osteoporotic fracture risk amid the diagnosis of HPT, we aimed to address this gap by analyzing the 10-year fracture risk assessment based on traditional FRAX (Fracture Risk Assessment Tool) model in comparison to the novel algorithm (FRAXplus), according to the adjustment for the presence of HPT, as well as for the use of lumbar bone mineral density (BMD) in menopausal women with HPT versus controls (non-HPT), respectively, between HC-HPT versus NC-HPT. Methods: For each patient, the latest algorithms of FRAX and FRAXplus provided the 10-year fracture risk for major osteoporotic fractures (MOF) and for hip fracture (HF) amid a single-center, retrospective, real-life study. Results: In total, 131 subjects were included: 51.15% had HPT (64.18% of them had HC-HPT) versus age-, menopause duration-, and body mass index-matched (HPT-free) controls. As a result, 10-year fracture risk for MOF and HF was statistically significantly higher in HPT versus controls only for the calculation with femoral neck BMD. FRAXplus showed that for both estimations (MOF and HF) with introduction of lumbar BMD remained higher than controls (4.55% vs. 3.7%, p = 0.004, respectively, 1.05% vs. 0.5%, p = 0.002). In HPT group, 10-year fracture risk for MOF and HF were higher if adjustment for HPT was applied. The highest 10-year fracture risk for MOF was obtained for HPT adjustment with femoral neck BMD (5.9%) versus the estimation without using femoral neck BMD (5.25%, p = 0.001), respectively, versus the probability with adjustment for lumbar BMD (4.55%, p &lt; 0.001). The same observation was for HF: 1.4% versus 1.2% (p = 0.028), respectively, versus 1.05% (p &lt; 0.001). In HPT group, parathormone level positively correlated with 10-year hip fracture risk with HPT adjustment, without femoral neck BMD (r = 0.257, p = 0.049). Bone formation marker P1NP negatively correlated with 10-year fracture risk for MOF without femoral neck BMD (r = \u22120.416, p = 0.043), respectively, with the estimation including HPT adjustment without femoral neck BMD (r = \u22120.404, p = 0.05), and with the 10-year HF risk calculated without femoral neck BMD (r = \u22120.407, p = 0.049). Conclusions: To our best knowledge, this is the first study to address the use of FRAXplus in HPT. The similar values between FRAX-based probabilities without the use of femoral neck BMD in HPT versus non-HPT controls suggested that this traditional estimation might not be so useful in HPT population, thus the need for novel models (HPT adjustment). HPT adjustment (FRAXplus) provided a higher MOF\/HF risk versus non-adjustment (FRAX). All 10-year probabilities based on FRAX and FRAXplus models showed similar values in HC-HPT versus NC-HPT, which implies that current algorithms might not make a clear distinction between HPT subtypes, yet the statistically significant results within each of these subgroups sustain the FRAXplus application regardless of the variant.<\/jats:p>","DOI":"10.3390\/life16060932","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T03:37:29Z","timestamp":1780544249000},"page":"932","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Future Directions in Hypercalcemic and Normocalcemic Primary Hyperparathyroidism: FRAXplus for 10-Year Fracture Risk Assessment (A Retrospective Study)"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5970-3701","authenticated-orcid":false,"given":"Ana-Maria","family":"Gheorghe","sequence":"first","affiliation":[{"name":"PhD Doctoral School, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Department of Endocrinology V, \u201cC.I. Parhon\u201d National Institute of Endocrinology, 011863 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana-Claudia","family":"Sima","sequence":"additional","affiliation":[{"name":"Department of Endocrinology V, \u201cC.I. Parhon\u201d National Institute of Endocrinology, 011863 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4748-6300","authenticated-orcid":false,"given":"Mihai","family":"Costachescu","sequence":"additional","affiliation":[{"name":"Department of Radiology and Medical Imaging, \u201cDr. Carol Davila\u201d Central Military University Emergency Hospital, 010825 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Ionovici","sequence":"additional","affiliation":[{"name":"Occupational Medicine Department, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8585-3835","authenticated-orcid":false,"given":"Mara","family":"Carsote","sequence":"additional","affiliation":[{"name":"PhD Doctoral School, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Department of Endocrinology V, \u201cC.I. Parhon\u201d National Institute of Endocrinology, 011863 Bucharest, Romania"},{"name":"Department of Endocrinology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.eprac.2025.07.009","article-title":"Management of Primary Hyperparathyroidism: Historical and Contemporary Perspectives","volume":"31","author":"Htoo","year":"2025","journal-title":"Endocr. Pract."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Lengyel, B., Armos, R., Bojtor, B., Kiss, A., Tobias, B., Piko, H., Illes, A., Horvath, E., Putz, Z., and Takacs, I. (2025). Vitamin D in Endocrine Disorders: A Broad Overview of Evidence in Musculoskeletal, Thyroid, Parathyroid, and Reproductive Disorders. Pharmaceuticals, 19.","DOI":"10.3390\/ph19010054"},{"key":"ref_3","first-page":"348","article-title":"Parathyroidectomy: Is vitamin D a player for a good outcome?","volume":"4","author":"Carsote","year":"2016","journal-title":"J. Med. Life"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s11154-024-09899-5","article-title":"Primary hyperparathyroidism: From guidelines to outpatient clinic","volume":"25","author":"Palermo","year":"2024","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.clinthera.2021.02.003","article-title":"Management of Primary Hyperparathyroidism With Severe Hypercalcemia During the COVID-19 Pandemic","volume":"43","author":"Alfadhli","year":"2021","journal-title":"Clin. Ther."},{"key":"ref_6","first-page":"545","article-title":"Muscle metastases from cervical carcinoma\u2014Case report","volume":"58","author":"Albulescu","year":"2017","journal-title":"Rom. J. Morphol. Embryol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Aojula, N., Ready, A., Gittoes, N., and Hassan-Smith, Z. (2021). Management of Parathyroid Disease during the COVID-19 Pandemic. J. Clin. Med., 10.","DOI":"10.3390\/jcm10050920"},{"key":"ref_8","first-page":"434","article-title":"Thyroid nodules after initial evaluation by primary health care practitioners: An ultrasound pictorial essay","volume":"51","author":"Dumitru","year":"2016","journal-title":"Arch. Balk. Med. Union"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.dsx.2020.05.050","article-title":"Managing common endocrine disorders amid COVID-19 pandemic","volume":"14","author":"Pal","year":"2020","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_10","first-page":"e44378","article-title":"Incidental Normocalcemic Primary Hyperparathyroidism Presenting With Symptomatic Hypophosphatemia: A Case Report","volume":"15","author":"Tabbikha","year":"2023","journal-title":"Cureus"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"109706","DOI":"10.1016\/j.surg.2025.109706","article-title":"Use of a Best Practice Advisory to increase the detection rate of hyperparathyroidism","volume":"189","author":"Gates","year":"2026","journal-title":"Surgery"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1210\/jc.2018-01225","article-title":"Primary Hyperparathyroidism","volume":"103","author":"Bilezikian","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_13","first-page":"129","article-title":"Hashimoto\u2019s thyroiditis and breast cancer: Coincidence or correlation?","volume":"51","author":"Valea","year":"2016","journal-title":"Arch. Balk. Med. Union"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s12020-024-03784-6","article-title":"New insights into the vitamin D\/PTH axis in endocrine-driven metabolic bone diseases","volume":"85","author":"Bilezikian","year":"2024","journal-title":"Endocrine"},{"key":"ref_15","first-page":"996","article-title":"Premenstrual dysphoric disorder: Neuroendocrine interferences","volume":"113","author":"Poiana","year":"2009","journal-title":"Rev. Med. Chir. Soc. Med. Nat. Iasi"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/jbmr\/zjae056","article-title":"Interactions between PTH and adiposity: Appetizing possibilities","volume":"39","author":"Bilezikian","year":"2024","journal-title":"J. Bone Miner. Res."},{"key":"ref_17","first-page":"10","article-title":"Multinodular and vacuolating neuronal tumor","volume":"CXXVIII","author":"Mitrica","year":"2025","journal-title":"Rom. J. Mil. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.revmed.2024.07.004","article-title":"Primary hyperparathyroidism: From diagnosis to treatment","volume":"46","author":"Carpentier","year":"2025","journal-title":"Rev. Med. Interne"},{"key":"ref_19","first-page":"36","article-title":"The Neurocardiogenic Impact of Ischemic Stroke: Intricacies of Cardiac Enzymes and the Vegetative System","volume":"CXXVIII","author":"Manea","year":"2025","journal-title":"Rom. J. Mil. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"689","DOI":"10.20945\/2359-3997000000558","article-title":"Medical management of primary hyperparathyroidism","volume":"66","author":"Bandeira","year":"2022","journal-title":"Arch. Endocrinol. Metab."},{"key":"ref_21","first-page":"67","article-title":"Case Management of Delirium in Patients with Major Neurocognitive Disorders","volume":"CXXVIII","author":"Vasiliu","year":"2025","journal-title":"Rom. J. Mil. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"116272","DOI":"10.1016\/j.amjsurg.2025.116272","article-title":"Patients with normocalcemic versus hypercalcemic hyperparathyroidism: What\u2019s really the difference?","volume":"244","author":"Balachandra","year":"2025","journal-title":"Am. J. Surg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e868","DOI":"10.1210\/clinem\/dgae659","article-title":"Approach to the Patient: Normocalcemic Primary Hyperparathyroidism","volume":"110","author":"Liu","year":"2025","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/jbmr.4677","article-title":"Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop","volume":"37","author":"Bilezikian","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1002\/jbmr.4682","article-title":"Management of Primary Hyperparathyroidism","volume":"37","author":"Bilezikian","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"115812","DOI":"10.1016\/j.amjsurg.2024.115812","article-title":"Normocalcemic primary hyperparathyroidism: From pathophysiology to clinical management","volume":"235","author":"Wu","year":"2024","journal-title":"Am. J. Surg."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/imj.15502","article-title":"Normocalcaemic primary hyperparathyroidism: Is nephrolithiasis more common than osteoporosis?","volume":"53","author":"Wu","year":"2023","journal-title":"Intern. Med. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"666","DOI":"10.20945\/2359-3997000000556","article-title":"Normocalcemic primary hyperparathyroidism","volume":"66","author":"Cusano","year":"2022","journal-title":"Arch. Endocrinol. Metab."},{"key":"ref_29","first-page":"2330","article-title":"Classical and Nonclassical Manifestations of Primary Hyperparathyroidism","volume":"37","author":"Chakhtoura","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.suc.2021.12.009","article-title":"Contemporary Management of Primary Hyperparathyroidism","volume":"102","author":"Slattery","year":"2022","journal-title":"Surg. Clin. N. Am."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.mcna.2021.05.017","article-title":"Evaluation and Management of Elevated Parathyroid Hormone Levels in Normocalcemic Patients","volume":"105","author":"Cusano","year":"2021","journal-title":"Med. Clin. N. Am."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s12020-021-02845-4","article-title":"A practical approach to normocalcemic primary hyperparathyroidism","volume":"74","year":"2021","journal-title":"Endocrine"},{"key":"ref_33","unstructured":"(2026, March 20). Available online: https:\/\/www.osteoporosis.foundation\/health-professionals\/diagnosis."},{"key":"ref_34","unstructured":"(2026, March 20). Available online: https:\/\/www.fraxplus.org\/calculation-tool."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11657-025-01626-0","article-title":"Utility of FRAX and FRAXplus in predicting prevalent radiographic vertebral fractures in postmenopausal women from a rural hospital in Southern India-FRACHAMB study (FRActure Christian Hospital AMBilikkai)","volume":"20","author":"Cherian","year":"2025","journal-title":"Arch. Osteoporos."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s00198-025-07588-w","article-title":"Effect of FRAXplus adjustments on fracture risk reclassification in older Swedish women-results from the SUPERB-study","volume":"36","author":"Zoulakis","year":"2025","journal-title":"Osteoporos. Int."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"472","DOI":"10.5694\/mja2.52637","article-title":"2024 Royal Australian College of General Practitioners and Healthy Bones Australia guideline for osteoporosis management and fracture prevention in postmenopausal women and men over 50 years of age","volume":"222","author":"Wong","year":"2025","journal-title":"Med. J. Aust."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2042018821995370","DOI":"10.1177\/2042018821995370","article-title":"Normocalcaemic primary hyperparathyroidism: What is the role of parathyroid surgery?","volume":"12","author":"Aojula","year":"2021","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1002\/lary.70382","article-title":"Algorithmic Surgical Management of Primary Hyperparathyroidism and Its Variants: A Scoping Review","volume":"136","author":"Kabala","year":"2026","journal-title":"Laryngoscope"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3803\/EnM.2021.1061","article-title":"Normocalcemic Primary Hyperparathyroidism: Need for a Standardized Clinical Approach","volume":"36","author":"Zavatta","year":"2021","journal-title":"Endocrinol. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/cen.14315","article-title":"Normocalcaemic primary hyperparathyroidism: An update on diagnostic and management challenges","volume":"93","author":"Dawood","year":"2020","journal-title":"Clin. Endocrinol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1210\/clinem\/dgaf625","article-title":"Cardiovascular Involvement in Primary Hyperparathyroidism","volume":"111","author":"Pepe","year":"2026","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11906-020-01108-3","article-title":"Endocrine Causes of Hypertension","volume":"22","author":"Cosentino","year":"2020","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Castellano, E., Attanasio, R., Boriano, A., Borretta, V., Tassone, F., and Borretta, G. (2021). Diabetes and Bone Involvement in Primary Hyperparathyroidism: Literature Review and Our Personal Experience. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.665984"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1038\/s41598-025-86954-4","article-title":"Calcium to magnesium ratio as a superior biomarker for nephrolithiasis detection in primary hyperparathyroidism","volume":"15","author":"Koca","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s42000-024-00530-5","article-title":"The clinical significance of calcium\/magnesium ratio in primary hyperparathyroidism: Unveiling a clinical association","volume":"23","author":"Tam","year":"2024","journal-title":"Hormones"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"9936658","DOI":"10.1155\/ije\/9936658","article-title":"Trends in Clinical Features of Primary Hyperparathyroidism During 2013\u20132024","volume":"2026","author":"Chen","year":"2026","journal-title":"Int. J. Endocrinol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00508-025-02670-z","article-title":"Bone metabolism in primary hyperparathyroidism","volume":"138","author":"Gelles","year":"2026","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/jbmr\/zjaf118","article-title":"Advances in Parathyroid Hormone-based medicines","volume":"40","author":"Bonnet","year":"2025","journal-title":"J. Bone Miner. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jss.2024.10.042","article-title":"Perioperative Bone Mineral Density Assessment in Patients With Primary Hyperparathyroidism","volume":"305","author":"Kirsch","year":"2025","journal-title":"J. Surg. Res."},{"key":"ref_51","first-page":"17455057241231387","article-title":"Use of Fracture Risk Assessment Tool in clinical practice and Fracture Risk Assessment Tool future directions","volume":"20","author":"Zerikly","year":"2024","journal-title":"Womens Health"},{"key":"ref_52","first-page":"363","article-title":"Assessment of fracture risk with FRAX and FRAXplus","volume":"160","author":"Tan","year":"2024","journal-title":"Gac. Med. Mex."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s40618-023-02219-9","article-title":"An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis","volume":"47","author":"Schini","year":"2024","journal-title":"J. Endocrinol. Investig."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Bischoff, E., Sewerin, P., B\u00fchring, B., Kirilov, N., and Baraliakos, X. (2026). Prevalence of Low Bone Density and Fracture Risk Assessed with the FRAX Tool in German Patients with Axial Spondyloarthritis: A Cross-Sectional Study. Life, 16.","DOI":"10.3390\/life16030439"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Ena, G., and Soyfoo, M. (2025). Postmenopausal Osteoporosis: From Molecular Pathways to Therapeutic Targets-A Mechanism-to-Practice Framework Integrating Pharmacotherapy, Fall Prevention, and Adherence into Patient-Centered Care. J. Clin. Med., 15.","DOI":"10.3390\/jcm15010102"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Delgado, J., Profit\u00f3s, J., Ar\u00e9valo, M., Lira, A., M\u00e1rmol, C., Miquel, M., Casas, M., Vergara, M., Calvet, X., and Berlanga, E. (2023). Osteoporosis and Fragility Fractures in Patients with Liver Cirrhosis: Usefulness of FRAX\u00ae as a Screening Tool. J. Clin. Med., 13.","DOI":"10.3390\/jcm13010188"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Chuang, T.L., Wang, Y.F., Koo, M., and Chuang, M.H. (2022). Association of Trabecular Bone Score-Adjusted Fracture Risk Assessment Tool with Coronary Artery Calcification in Women. Diagnostics, 12.","DOI":"10.3390\/diagnostics12010178"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Bischoff, E., Vladeva, S., Baraliakos, X., and Kirilov, N. (2026). AI-Powered Lateral DEXA Morphometry for Integrated Evaluation of Thoracic Kyphosis and Bone Density Assessment in Patients with Axial Spondyloarthritis. Life, 16.","DOI":"10.3390\/life16010162"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.eprac.2024.10.005","article-title":"Parathyroidectomy Reduces Inflammatory Cytokines and Increases Vitamin D Metabolites in Patients With Primary Hyperparathyroidism","volume":"31","author":"Meng","year":"2025","journal-title":"Endocr. Pract."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e081250","DOI":"10.1136\/bmj-2024-081250","article-title":"Advances in the management of osteoporosis","volume":"390","author":"Hoong","year":"2025","journal-title":"BMJ"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1007\/s40618-025-02590-9","article-title":"Trabecular bone score as a possible new surgical recommendation in patients with asymptomatic primary hyperparathyroidism","volume":"48","author":"Bisceglia","year":"2025","journal-title":"J. Endocrinol. Investig."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1007\/s11547-025-02004-z","article-title":"Advanced radiomic prediction of osteoporosis in primary hyperparathyroidism: A machine learning-based analysis of CT images","volume":"130","year":"2025","journal-title":"Radiol. Med."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Corbetta, M., Carrara, S., Dal Lago, A., Mirsepanj, R., Ruotolo, E., Sardella, C., Leo, G., Cetani, F., and Corbetta, S. (2026). Effects of Gender, Menopause, Vitamin D Status, and Tumor Parathyroid Cell Activity on Serum Phosphate Levels in a Large Cohort of Patients with Sporadic Hypercalcemic Primary Hyperparathyroidism. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27042012"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/6\/932\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:13:21Z","timestamp":1780546401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/6\/932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":63,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["life16060932"],"URL":"https:\/\/doi.org\/10.3390\/life16060932","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}